Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
13.00
+0.03 (0.23%)
Jul 30, 2026, 10:28 AM EDT - Market open
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $318.56 million as of July 30, 2026. Its market cap has increased by 66.89% in one year.
Market Cap
318.56M
Enterprise Value
105.70M
1-Year Change
66.89%
Ranking
Category
Stock Price
$13.00
ChartMarket Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $318.56M, a decrease of -92.28%. That is a compound annual growth rate of -39.36%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 30, 2026 | 318.56M | -51.28% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lexeo Therapeutics | 347.85M |
| Upstream Bio | 347.20M |
| Clinuvel Pharmaceuticals | 345.17M |
| Abeona Therapeutics | 340.83M |
| Atea Pharmaceuticals | 332.11M |
| Vicore Pharma Holding AB | 326.47M |
| Zentalis Pharmaceuticals | 326.03M |
| Vanda Pharmaceuticals | 309.10M |